<![CDATA[Retrospective Data Show Potential Real-World TTNT and OS Improvements With Next-Generation BTK Inhibitors in R/R MCL]]>

Real-World Study of Covalent BTK Inhibitor Outcomes in R/R MCLA retrospective real-world study found that zanubrutinib was associated with significantly longer OS than ibrutinib in patients with relapsed/refractory MCL treated with a covalent BTK inhibitor in the second- or third-line setting.Patients receiving zanubrutinib also experienced numerically longer time to next treatment compared with both ibrutinib and acalabrutinib.Researchers noted that treatment discontinuation was most often driven by disease progression or toxicity, and they called for further studies to better understand differences among covalent BTK inhibitors in real-world practice.